Recurrent Platinum-Resistant Ovarian Carcinoma (DBCOND0131677)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06483048	MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer	Bendamustine Cyclophosphamide	treatment	1	recruiting
NCT03113487	P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Modified vaccinia ankara Pembrolizumab	treatment	2	active_not_recruiting
NCT05691504	Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	Cobimetinib Pelcitoclax	treatment	1	recruiting
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Bevacizumab Pembrolizumab	treatment	2	recruiting
NCT04739800	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents	Cediranib Doxorubicin Durvalumab Olaparib Paclitaxel Tetracycline Topotecan	treatment	2	active_not_recruiting
NCT02839707	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Atezolizumab Bevacizumab Doxorubicin Tetracycline	treatment	2 / 3	active_not_recruiting
NCT04840589	Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors	Ipilimumab Nivolumab	treatment	1	recruiting
NCT06393751	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer	Bevacizumab Paclitaxel Tolinapant	treatment	1 / 2	not_yet_recruiting
NCT04633239	Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer	Abemaciclib Olaparib	treatment	1	recruiting
NCT05295589	Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy	Copanlisib Doxorubicin Olaparib Paclitaxel Tetracycline Topotecan	treatment	2	withdrawn
NCT05026606	Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Etigilimab Nivolumab	treatment	2	active_not_recruiting